Revolutionizing TB Treatment
Starting next month, the Maharashtra government will implement a six-month treatment regimen for drug-resistant tuberculosis (TB), significantly reducing the current two-year treatment duration. Public health officials emphasize that the new drug regimen will enhance adherence and lower mortality rates.
Implementation Under National TB Elimination Programme (NTEP)
The new drug regimen, known as BPaL/BPaLM, will be administered to all adult patients under the National TB Elimination Programme (NTEP). It includes the medications bedaquiline, pretomanid, linezolid, and moxifloxacin. Officials confirm that all multi-drug-resistant TB (MDR-TB) patients will receive this improved treatment protocol.
Ensuring Patient Compliance and Effectiveness
Dr. Sandeep Sangale, Joint Director (TB and Leprosy), Maharashtra, highlights the advantages of the new regimen. He states, “This new drug regime is proven to be safer, more effective, and quicker compared to the previous MDR-TB treatment procedure. A shorter treatment period will enhance patient compliance.”
Maharashtra has already received four batches of medicine and distributed them to Nodal Drug-Resistant TB (DR-TB) centers across the state. Officials expect additional stock and updated guidelines soon.
Expanding TB Treatment Facilities
To improve accessibility, the Public Health Department has established 21 nodal DR-TB centers for drug-resistant TB treatment. Additionally, 42 district DR-TB centers provide conventional MDR-TB treatment, ensuring patients receive appropriate care near their homes.
Successful Pilot Project in Mumbai
Dr. Nitin Bhalerao, Assistant Director (TB and Leprosy), Maharashtra, reveals that Mumbai’s TB division piloted the new drug regimen a year ago, yielding positive results. Based on this success, the government will roll out the treatment across the state next month.
As reported by hindustantimes, currently, treatment for drug-resistant TB patients varies between nine months and two years. The shorter regimen will provide a significant breakthrough in treatment duration and effectiveness.
Financial Support for TB Patients
Since April 2018, TB patients under the NTEP have been receiving financial aid through direct benefit transfers (DBT) for nutritional support. Under the Nikshay Poshan Yojana, patients receive ₹1,000 per month directly in their bank accounts. In 2024, Maharashtra disbursed ₹29.01 crore to support TB patients.
Conclusion
The introduction of the six-month BPaL/BPaLM regimen marks a significant step in Maharashtra’s fight against drug-resistant TB. With improved adherence, reduced mortality, and better patient outcomes, this initiative aligns with India’s commitment to eliminating TB.